Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-054739
Filing Date
2018-10-10
Accepted
2018-10-10 19:32:53
Documents
2
Period of Report
2018-10-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2822
2 POA DOCUMENT poa.txt EX-24.3_813291 3056
  Complete submission text file 0001209191-18-054739.txt   7261
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
MESSEMER DEBORAH M. (Reporting) CIK: 0001754424 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 181117066